Beone Medicines Ltd.
An oncology-focused biopharmaceutical company that develops and sells medicines for blood cancers, including Brukinsa, used to treat leukemia and lymphoma. Founded in Beijing in 2010 by John Oyler and Xiaodong Wang, it was originally called BeiGene — a blend of "Beijing" and "gene" — before rebranding as BeOne in 2024, a name chosen to reflect its mission against cancer: "Be" stands for patients' goal to be free of disease, and "One" for uniting people in that fight.
American Depositary Receipt (each representing 13 ordinary shares)
Sold 17.84M
Granted 10.01M · Sold 544.2K
Granted 638.4K · Sold 350.8K
Granted 147.3K · Sold 2.88M
Granted 1.04M · Sold 31.8K
Granted 16.3K
Granted 1.09M · Sold 291.3K
Granted 136.2K · Sold 2.7K
Granted 357.2K · Sold 45.5K
Granted 85.2K · Sold 698
Granted 46.3K
Granted 46.3K · Sold 212
Granted 46.3K · Sold 212
Granted 32.6K · Sold 5.5K
Granted 46.3K
Granted 27.3K · Sold 235
Granted 19.0K
Granted 19.0K
Granted 38.1K
Granted 421.6K · Sold 1.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| HHLR Advisors, LTD. +1 co-filer10% owner · 1 transaction | -12.5% | 125.05Mas of Dec 2024 | — | — | 17.84M |
| Oyler JohnChief Executive Officer, Director · 158 transactions | — | 95.85M | 10.01M | — | 544.2K |
| Wang XiaodongDirector, Chair, Scientific Advisory Brd · 96 transactions | -8.7% | 14.82M | 638.4K | — | 350.8K |
| Baker Bros. Advisors LP +5 co-filersDirector · 18 transactions | — | 8.54M | 147.3K | — | 2.88M |
| Wang LaiPresident, Global Head of R&D · 39 transactions | +68.1% | 2.88M | 1.04M | — | 31.8K |
| Glazer Donald W.Director · 2 transactions | -2.4% | 2.72Mas of Jun 2024 | 16.3K | — | — |
| Wu XiaobinPresident and COO · 90 transactions | +26.6% | 1.29M | 1.09M | — | 291.3K |
| Wang Julia AijunChief Financial Officer · 8 transactions | +31.2% | 426.6Kas of Jul 2024 | 136.2K | — | 2.7K |
| Lee Chan HenrySVP, General Counsel · 77 transactions | +97.8% | 338.9K | 357.2K | — | 45.5K |
| Ball Titus B.Principal Accounting Officer · 10 transactions | — | 99.6K | 85.2K | — | 698 |
| Hooper Anthony CDirector · 3 transactions | +123.8% | 83.7K | 46.3K | — | — |
| Dugan MargaretDirector · 4 transactions | +147.1% | 73.2K | 46.3K | — | 212 |
| Riva AlessandroDirector · 4 transactions | +147.1% | 73.2K | 46.3K | — | 212 |
| Sanders Corazon (Corsee) D.Director · 8 transactions | +82.2% | 54.5K | 32.6K | — | 5.5K |
| Brandicourt OlivierDirector · 3 transactions | — | 46.3K | 46.3K | — | — |
| Yi QingqingDirector · 4 transactions | -18% | 24.3K | 27.3K | — | 235 |
| Mooney Elizabeth FisherDirector · 1 transaction | — | 19.0K | 19.0K | — | — |
| Sawyers Charles LazelleDirector · 1 transaction | — | 1.9K | 19.0K | — | — |
| Sharp ShaliniDirector · 3 transactions | — | 9 | 38.1K | — | — |
| Rosenberg AaronChief Financial Officer · 8 transactions | — | 0 | 421.6K | — | 1.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -22.00M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.